This Medical News story discusses research that identifies a positive association between oral microbiome dysbiosis and pancreatic cancer.
This randomized trial compares the effects of induction gemcitabine with vs without erlotinib in patients with locally advanced pancreatic cancer and, among those responsive to treatment, compares the effects of chemotherapy with vs without radiation.
Schultz and coauthors report preliminary data on microRNA biomarkers in whole blood for detection of pancreatic cancer. In an accompanying Editorial, Buchsbaum and Croce discuss whether detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer.
To analyze whether previously reported improvement in disease-free survival with adjuvant gemcitabine therapy translates into improved overall survival, Oettle and coauthors conducted a multicenter, open-label, phase 3 randomized trial to evaluate the efficacy and toxicity of gemcitabine in patients with pancreatic cancer after complete tumor resection.